Get the Stockscreener App
26.78
0.26%
-0.07
Alto Neuroscience Inc stock is traded at $26.78, with a volume of 295.56K.
It is down -0.26% in the last 24 hours and up +7.51% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$26.85
Open:
$27.28
24h Volume:
295.56K
Relative Volume:
0.63
Market Cap:
$1.04B
Revenue:
-
Net Income/Loss:
$-74.31M
P/E Ratio:
-10.79
EPS:
-2.4817
Net Cash Flow:
$-62.86M
1W Performance:
-2.76%
1M Performance:
+7.51%
6M Performance:
+61.23%
1Y Performance:
+769.48%
1-Day Range:
$25.72
$27.89
1-Week Range:
$25.66
$28.63
52-Week Range:
$3.00
$28.85
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
26.78 | 1.04B | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Alto Neuroscience, Inc. Revenue Breakdown – NYSE:ANRO - TradingView
EcoR1 Capital discloses 5.8% Alto Neuroscience (ANRO) stake in Schedule 13G - Stock Titan
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
Alto Neuroscience Raises Capital to Advance ALTO-207 - TipRanks
Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE - Minichart
Form 424B5 Alto Neuroscience Inc For: 14 July By Investing.com - Investing.com Nigeria
Alto Neuroscience (NYSE: ANRO) sells 3,776,436 shares at $26.48 - Stock Titan
Alto Neuroscience Launches $93.9M Stock Offering at $26.48 in BofA-Led Underwriting - TradingView
Alto Neuroscience (NYSE: ANRO) to raise $93.9M in stock sale - Stock Titan
Alto Neuroscience Prices $100 Million Stock Offering - Moomoo
Latham Advises on Alto Neuroscience’s US$100 Million Underwritten Registered Direct Offering of Common Stock - Latham & Watkins LLP
Alto Neuroscience prices $100M stock offering at $26.48 - Investing.com UK
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Alto Neuroscience Inc (ANRO) is planning to accelerate and expand the clinical development of its candidate drug Alto-207 by adding a new phase III clinical trial. - Bitget
Alto Neuroscience prices $100M stock offering at $26.48 By Investing.com - Investing.com Australia
Alto Neuroscience (ANRO) Prices $100 Million Stock Offering - GuruFocus
Alto Neuroscience Highlights Strong Cash, Expands ALTO-207 Trials - TipRanks
Alto Neuroscience (ANRO) Files Form 8-K Announcing Phase 3 Trial Plans for ALTO-207 in Treatment-Resistant Depression – Minichart - Minichart
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock - Business Wire
Alto Neuroscience (NYSE: ANRO) estimates $244.2M cash and plans added ALTO-207 Phase 3 - Stock Titan
Alto Neuroscience, Inc. Stock 12‑Month Price Target Cut to $34.8, Implies 33% Upside - TradingView
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - AOL.com
Alto Neuroscience (ANRO) Edges Lower as Shares Test Key Support ZoneEquity Put Call - dars.gov.et
ANROAlto Neuroscience Inc Latest SEC Filings - Finviz
Price to sales forward of Alto Neuroscience, Inc. – NYSE:ANRO - TradingView
Price to earnings forward of Alto Neuroscience, Inc. – NYSE:ANRO - TradingView
Alto Neuroscience (ANRO) Holds Near Support Amid Slight Dip – Key Levels in FocusIceberg Order - dars.gov.et
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The National Law Review
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Yahoo Finance
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider Loss Per Share on Higher R&D SpendingLow Estimate Range - dars.gov.et
Alto Neuroscience, Inc.(NYSE:ANRO) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 3000 Growth Benchmark - marketscreener.com
Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Sharehol - The National Law Review
Investors SueWallSt as Alto Neuroscience, Inc. Faces Securities Fraud Allegations - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. C - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Alto Neuroscience, Inc. (ANRO) Class Action Lawsuit: Levi & Korsi - The National Law Review
Securities Lawsuit Alert: Alto Neuroscience, Inc. (ANRO)Contact Levi & Korsinsky Before September 19, 2025 - The National Law Review
H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience, Inc. Actuals & Estimates (BOATS:ANRO) - TradingView
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Alto Neuroscience Inc (ANRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alto Neuroscience (ANRO) Surges 4.36% as Stock Approaches Key Resistance LevelBreadth Thrust - dars.gov.et
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point - Stocktwits
Alto Neuroscience Inc (ANRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):